Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 301 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Infusion -Healthy Clear all

Conditions: Fibrosis
Interventions: BMS-986263, Placebo, Diphenhydramine, Famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: CD101 IV, Placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: DISC-3405, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Parkinson's Disease, Healthy
Interventions: BIIB054, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more

Conditions: Healthy
Interventions: AZD1613, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Alzheimer's Disease
Interventions: CTS21166 (ZPQ-21166); Drug
Lead sponsor: CoMentis; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: ABBV-142, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Influenza
Interventions: VIS410, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Subjects
Interventions: Placebo, MEDI7814, 1 MG/KG, MEDI7814, 3 MG/KG, MEDI7814, 10 MG/KG, MEDI7814, 20 MG/KG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cardiovascular Disease
Interventions: INS50589 Intravenous Infusion; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Covid19
Interventions: sotrovimab, Placebo to Biologic; Biological · Other
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Anaheim, California • Glendale, California

Conditions: Frailty
Interventions: Ghrelin Infusion - Healthy, Ghrelin Infusion - Frail, Placebo Infusion -Healthy, Placebo Infusion - Frail; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 70 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ebola Hemorrhagic Fever
Interventions: AVI-7537, Normal Saline Solution (NSS); Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Parkinson's Disease
Interventions: PRX002, Placebo; Drug · Other
Lead sponsor: Prothena Biosciences Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: H1N1 Influenza Healthy Volunteers
Interventions: CR6261, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Subjects
Interventions: Ketamine, Nicotine, Placebo, Ketamine and Nicotine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Healthy
Interventions: STSA-1005 injection, Placebo; Drug
Lead sponsor: Staidson Biopharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute Ischemic Stroke
Interventions: NTS-104 TRIS, Placebo; Drug
Lead sponsor: NeuroTrauma Sciences, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Serious Gram-negative Infections
Interventions: Intravenous infusions of WCK 5222, Placebo; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Conditions: Healthy
Interventions: AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

A Study of DISC-3405 in Healthy Volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

Safety Study of CTS21166 to Treat Alzheimer Disease

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

A Study of VIS410 to Assess Safety and Pharmacokinetics

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Ghrelin in Healthy and Frail Older Women

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Single Ascending Dose Study of PRX002 in Healthy Subjects

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)